Alterations in lipid kinetics in men with HIV-dyslipidemia

Am J Physiol Endocrinol Metab. 2003 Sep;285(3):E490-7. doi: 10.1152/ajpendo.00118.2003. Epub 2003 May 13.

Abstract

Hypertriglyceridemia is common in individuals with human immunodeficiency (HIV) infection, but the mechanisms responsible for increased plasma triglyceride (TG) concentrations are not clear. We evaluated fatty acid and VLDL-TG kinetics during basal conditions and during a glucose infusion that resulted in typical postprandial plasma glucose and insulin concentrations in six men with HIV-dyslipidemia [body mass index (BMI): 28 +/- 2 kg/m2] and six healthy men (BMI: 26 +/- 2 kg/m2). VLDL-TG secretion and palmitate rate of appearance (Ra) in plasma were measured by using stable-isotope-labeled tracer techniques. Basal palmitate Ra and VLDL-TG secretion rates were greater (P < 0.01 for both) in men with HIV-dyslipidemia (1.04 +/- 0.07 micromol palmitate x kg-1 x min-1 and 5.7 +/- 0.6 micromol VLDL-TG x l plasma-1 x min-1) than in healthy men (0.67 +/- 0.08 micromol palmitate. kg-1 x min-1 and 3.0 +/- 0.5 micromol VLDL-TG x l plasma-1 x min-1). Basal VLDL-TG plasma clearance was lower in men with HIV-dyslipidemia (13 +/- 1 ml/min) than in healthy men (19 +/- 2 ml/min; P < 0.05). Glucose infusion decreased palmitate Ra (by approximately 50%) and the VLDL-TG secretion rate (by approximately 30%) in both groups, but the VLDL-TG secretion rate remained higher (P < 0.05) in subjects with HIV-dyslipidemia. These findings demonstrate that increased secretion of VLDL-TG and decreased plasma VLDL-TG clearance, during both fasting and fed conditions, contribute to hypertriglyceridemia in men with HIV-dyslipidemia. Although it is likely that increased free fatty acid release from adipose tissue contributes to the increase in basal VLDL-TG concentration, other factors must be involved, because insulin-induced suppression of lipolysis and systemic fatty acid availability did not normalize the VLDL-TG secretion rate.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Antiretroviral Therapy, Highly Active
  • Blood Glucose
  • Cholesterol, VLDL / pharmacokinetics*
  • Glucose / administration & dosage
  • HIV-Associated Lipodystrophy Syndrome / drug therapy
  • HIV-Associated Lipodystrophy Syndrome / metabolism*
  • Humans
  • Hyperglycemia / metabolism
  • Hyperinsulinism / metabolism
  • Hypertriglyceridemia / metabolism
  • Hypertriglyceridemia / virology*
  • Insulin / blood
  • Isotopes
  • Kinetics
  • Male
  • Middle Aged
  • Palmitates / pharmacokinetics
  • Triglycerides / pharmacokinetics*

Substances

  • Blood Glucose
  • Cholesterol, VLDL
  • Insulin
  • Isotopes
  • Palmitates
  • Triglycerides
  • Glucose